TRIF is a association of 2 person F&S in gold, copper, nickel, rare earths & pharma. We hold high-quality long-term companies aligned with a 20y vision.
$ABCL
-Truist raises AbCellera target to $30 from $12 on phase 2 ABCL635 trial results
-Truist now estimates peak risk-adjusted sales of $1.1 billion for the program, up from $641 million previously
-Reiterates Buy rating
https://t.co/7umUrGqJIE
Western Union's Stablecard is live.
Remittances can now arrive as stablecoins and be spent instantly anywhere Visa is accepted.
Mobile app, embedded wallets, and cards powered by Rain.
$100B a year for 100M customers is moving onchain.
Deep value or value trap. We’ll see.
I believe one day biotech will experience the same kind of mania semiconductors did.
I dont like $RGC.
What your best biotech for the 5 next years ?
Not advice. Only talking facts
$ABCL $CTMX $CRVS $LBRX $KYMR
Some wild thoughts crossed my mind…
Could $ABCL be the next $RGC?
📉 $ABCL IPO’d at $60 in 2020… now trading around $3.
🚀 $RGC saw a 20,000% share price explosion in just 4 months.
Watching $XBI closely.
Not a promoter—just sharing facts.
$VRTX $ABCL
AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions
• BioPharmCatalyst https://t.co/j7Zk4zmanv
BNN Lyle Stein Top Picks:
🌊 $XOM Exxon Mobil Today $154.53 Target $166.35 27X
🌊 $EWY MSCI South Korea ETF Today $157.88
🌊 $SYK Stryker Today $336.18 Target $387.58 22X
Lyle is normally Long Only and hold estimating with 4 years price targets. His firm does not generally trade. If the stock reaches the target price, he will sell.
Lyle and firm own all 3
Charles Lapierre student Top pick 18 avril TSX
$ELD.TO Gold+ $FOM.TO /Leverage/Rerate | PT 70-82
$SIS.TO Aging/Quality/Exec | PT 31-35
$BDT.TO Backlog/Infra/Disc+Carney infra Bill 50+B$ | PT 44-55
$WSP.TO Comp/Infra/M&A | PT 320-375
Not financial advice,
Only in simulation
Canadian stocks climbed Tuesday despite US President Donald Trump threatening 50% tariffs on the country’s exports, thanks to surging gold prices and a rally in tech hardware stocks https://t.co/neVs5djui6
Eli Lilly $LLY is reportedly in talks to acquire psychedelic drugmaker AtaiBeckley $ATAI, per Bloomberg.
A deal could be announced as soon as this week.
AtaiBeckley has a market value of about $2B, and Lilly is reportedly negotiating at a premium.
The key asset is BPL-003, a fast-acting nasal spray for treatment-resistant depression that has FDA Breakthrough Therapy designation.
Bloomberg Intelligence estimates the psychedelic treatment market could reach $7B in sales by 2032.